Phase 4 Study of Acthar Gel Enrolls First SLE Patients with Active Disease
Mallinckrodt Pharmaceuticals announced the enrollment of the first patients in the company’s Phase 4 clinical trial of H.P. Acthar Gel (repository corticotropin injection) for the treatment of systemic lupus erythematosus (SLE) patients with persistently active disease. The randomized and double-blind study (NCT02953821) will assess the effectiveness of the gel against…